[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"content-doc-dcio10d29ba9":3},{"user":4,"document":8,"mainDocument":30,"columnUrl":32,"subscription":33,"footer":45,"text":80},{"isAuthenticated":5,"isAdmin":5,"displayName":6,"avatarUrl":6,"nid":6,"groupLevel":7},false,"",-10,{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":21,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":26,"videoId":6,"liveVideoUrl":6,"duration":27,"price":27,"priceText":28,"priceBadgeText":28,"priceBadgeClass":29,"freeForMinGroupLevel":27,"redirectUrl":6,"readyToStream":5},"dcio10d29ba9","英伟达 盘后突发！加仓一只票！","\u002Fdoc\u002Fdcio10d29ba9","col18178739ee","美股资讯","\u002Fcol\u002Fcol18178739ee","\u003Cp>英伟达NVDA 提交了第二季度 13F 报告，加仓了CRWV 95000股，占其投资组合的 91%，价值39亿美元\u003C\u002Fp>\n\u003Cfigure class=\"image\" data-img-size-val=\"867,289\">\u003Cimg src=\"https:\u002F\u002Fimg.36krcdn.com\u002Fhsossms\u002F20250816\u002Fv2_d9cbf6af30444263963b9ccb0e9fdbac@5576020_oswg41012oswg867oswg289_img_000\">\u003C\u002Ffigure>\n\u003Cp>持仓共 6 只股票：\u003C\u002Fp>\n\u003Cp>$CRWV – 91.36%\u003C\u002Fp>\n\u003Cp>$ARM – 4.11%\u003C\u002Fp>\n\u003Cp>$APLD – 1.79%\u003C\u002Fp>\n\u003Cp>$NBIS – 1.52%\u003C\u002Fp>\n\u003Cp>$RXRX – 0.90%\u003C\u002Fp>\n\u003Cp>$WRD – 0.32%\u003C\u002Fp>\n\u003Cp>\u003Cstrong>盘后 NVO 大涨7%\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cfigure class=\"image\" data-img-size-val=\"552,147\">\u003Cimg src=\"https:\u002F\u002Fimg.36krcdn.com\u002Fhsossms\u002F20250816\u002Fv2_330ea5367eb04312abafb1a76300e427@5576020_oswg24298oswg552oswg147_img_000\">\u003C\u002Ffigure>\n\u003Cp>美国食品药品监督管理局（FDA）加速批准了诺和诺德公司的Wegovy®（司美格鲁肽2.4mg）用于治疗患有中度至重度肝纤维化（F2至F3阶段）的非肝硬化代谢功能障碍相关脂肪性肝炎（MASH）成人。这一批准为诺和诺德打开了新的临床市场。目前，Wegovy成为首个获批用于MASH治疗的GLP-1药物，美国约5%的成年人受到MASH影响，表明该药有非常大的新增需求潜力。\u003C\u002Fp>\n\u003Cp>\u003Cstrong>对诺和诺德收入的影响\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>患者群体扩大：此次新适应症将Wegovy的目标人群从肥胖扩展到了慢性肝病患者，在美国覆盖人群可能数十万，进一步扩大潜在市场规模。\u003C\u002Fp>\n\u003Cp>销售增长预期：2025年第二季度，Wegovy的销售额同比增长67%，达到30.4亿美元，公司整体销售额同比增长13%，达到119.5亿美元。不过由于市场扩张趋缓和激烈竞争（包括司美格鲁肽仿制药及其他竞争产品），诺和诺德对全年收入增长的预期较为保守，为8%-14%。\u003C\u002Fp>\n\u003Cp>价格与竞争压力：尽管获批适应症有望拉动收入，但仿制产品和礼来等竞争对手的压力，可能导致价格下调，以加快市场推广并解决支付问题。\u003C\u002Fp>\n\u003Cp>未来展望：Wegovy新增适应症（如MASH）是诺和诺德未来的增长支柱，公司管理层也将继续加大投入，推动该产品在医生和患者中的认知与普及。新适应症带来的收入提升，取决于医保覆盖、真实用药率和竞争格局。\u003C\u002Fp>\n\u003Cp>\u003Cstrong>综上所述：\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>FDA的这一批准为诺和诺德打开了重要的新市场，预计将在未来几年显著提升Wegovy相关收入。具体增幅还需看市场转化速度、定价、竞争以及医保支付等因素。总体来说，该批准为Wegovy的商业前景提供了重要支撑，但在公司整体增速趋缓和市场竞争加剧的背景下，收入提升可能有一定的不确定性。\u003C\u002Fp>\n\u003Cp>\u003Cstrong>巴菲特建仓 UNH 爆涨13%，成本312美元\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cfigure class=\"image\" data-img-size-val=\"472,146\">\u003Cimg src=\"https:\u002F\u002Fimg.36krcdn.com\u002Fhsossms\u002F20250816\u002Fv2_71c3e265ec154a65a4624f31a2075bde@5576020_oswg18479oswg472oswg146_img_000\">\u003C\u002Ffigure>\n\u003Cp>而早在两个月前，UNH大跌到260美元，我们美股投资网就提醒全体VIP社群入场，成本比巴菲特低50美元\u003C\u002Fp>\n\u003Cp>截图曝光\u003C\u002Fp>\n\u003Cp>\u003Cimg style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202508-stk\u002F1170749384 %281%29.png\" alt=\"\">\u003C\u002Fp>\n\u003Cp>上个月，我们也做了一期深度视频分析，为什么我们要抄底 UNH\u003C\u002Fp>\n\u003Cp>妥妥马前炮\u003C\u002Fp>","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202508-stk\u002FUploader5gtlaf0ge2c_2025_08_15_17_19_20.jpeg","2025-08-16T00:17:21.857","2025.08.16","2025\u002F08\u002F16",57759,[22,23,24,25],"NVDA","CRWV","UNH","NBIS","Article",0,"免费","success",{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":31,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":26,"videoId":6,"liveVideoUrl":6,"duration":27,"price":27,"priceText":28,"priceBadgeText":28,"priceBadgeClass":29,"freeForMinGroupLevel":27,"redirectUrl":6,"readyToStream":5},[22,23,24,25],"\u002Fcol\u002Fstocknews",{"visible":5,"marketingHtml":34,"services":35,"recentDocuments":44},"\u003Cfigure class=\"image\">\u003Ca href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\" target=\"_blank\" rel=\"noopener noreferrer\">\u003Cimg style=\"display:block;margin-left:auto;margin-right:auto;\" src=\"https:\u002F\u002Fstockwewebfiles.blob.core.windows.net\u002Fweb-202408-stk\u002F1586109431mceclip0.jpg\">\u003C\u002Fa>\u003C\u002Ffigure>\u003Cdiv class=\"text-center\">\u003Ch2 class=\"card-title mx-auto\">\u003Cbr>\u003Ca target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\">案例介绍：英伟达深度研究报告\u003C\u002Fa>\u003C\u002Fh2>\u003C\u002Fdiv>",[36,40],{"productId":37,"serviceName":38,"priceText":39},"prod_PPxdDdK87QaiLv","月付","$12.95美元",{"productId":41,"serviceName":42,"priceText":43},"prod_PPxeMs3bix1da5","年付","$149.00美元",[],{"links":46,"images":71,"summaryHtml":76,"aboutTitle":77,"aboutHtml":78,"copyrightHtml":79},[47,50,53,56,59,62,65,68],{"label":48,"url":49},"深度报告","\u002Fcol\u002FdepthReport",{"label":51,"url":52},"VIP会员","\u002Fplan",{"label":54,"url":55},"期权推荐","\u002FOption",{"label":57,"url":58},"低价暴涨股","\u002FPenny",{"label":60,"url":61},"常见问题","https:\u002F\u002Fstockwe.com\u002FFAQ",{"label":63,"url":64},"美股课程","\u002Fcol\u002Fvideos",{"label":66,"url":67},"免责声明","\u002Fdisclaimer",{"label":69,"url":70},"联系我们","\u002FContactUs",[72,73,74,75],"https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploaderzic2tuwsol2_2025_09_11_18_21_07.gif","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploadercakzdvydksw_2025_09_03_09_00_56.png","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploadergtjyagwvoyk_2025_09_14_08_32_05.png","https:\u002F\u002Fstockwebsiteblob.blob.core.windows.net\u002Fweb-202509-stk\u002FUploader3u0tt4jhlqh_2025_09_23_22_30_48.png","邮箱: buy@TradesMax.com 美国电话 626-378-3637","公司介绍","\u003Cp class=\"MsoNormal\">美股大数据 StockWe.com 是一个美国领先的金融和美股信息大数据提供商，紧盯华尔街金融市场和行情，2008年成立于美国硅谷，创始人是前纽约证券交易所资深分析师Ken，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化交易模型，每天处理千万级股票数据：挖掘潜力大牛股，捕捉期权异动大单，实时主力资金流向、机构持仓变化、川普突发新闻，精准买卖信号第一时间发到您手机APP。\u003C\u002Fp>","专业美股投资者都在这里",{"loading":81,"search":82,"searchPlaceholder":82,"hotContent":83,"draft":84,"noData":85,"searchNoData":86,"edit":87,"editVideo":88,"courseContent":89,"more":90,"buyNow":91,"subscribeNow":92,"encoding":93,"paidContent":94},"Loading...","搜索","热门内容","草稿","目前没有任何内容公布","当前检索内容没有数据","编辑","编辑视频","课程内容","更多","立即购买后观看","- 立即订阅 -","视频编码中...","付费内容"]